- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 64
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 455
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer
- Interventions
- The radon app, Print brochure
- Other
- Lead sponsor
- University of North Dakota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Grand Forks, North Dakota
- Conditions
- Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
- Interventions
- Biological G207
- Biological
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • New York, New York • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Clinical High Risk, Psychosis, Prodromal, Schizophrenia
- Interventions
- Compensatory Cognitive Training, Recreational Therapy
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
- Interventions
- Erythropoietin, Saline placebo
- Drug
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- Up to 24 Hours
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Morristown, New Jersey
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Regular pasta, High protein pasta, White rice
- Other
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Breast Cancer
- Interventions
- Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more
- Conditions
- First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
- Interventions
- Screening Method (SM), Screening and Communication Method (SCM)
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- rHSC-DIPGVax, Balstilimab, Zalifrelimab
- Biological · Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Orange, California • Chicago, Illinois • Boston, Massachusetts
- Conditions
- Renal Disease
- Interventions
- assessment
- Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 2,575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- Huntsville, Alabama • Bakersfield, California • Chatsworth, California + 14 more
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Borderline High LDL-cholesterol
- Interventions
- Ubiquinol, Ubiquinone, Placebo
- Dietary Supplement · Other
- Lead sponsor
- SF Research Institute, Inc.
- Network
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
- Conditions
- Sinusitis
- Interventions
- standard dose amoxicillin/clavulanate, high dose amoxicillin/clavulanate
- Drug
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Latham, New York
- Conditions
- Skin Laxity
- Interventions
- Sofwave, Ultherapy
- Device
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis，MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
- Interventions
- Not listed
- Lead sponsor
- MPN Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 24
- States / cities
- Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 20 more
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Vosaroxin
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypertension, Hypertension (HTN), Blood Pressure, High, Blood Pressure Control
- Interventions
- Standard medical treatment, Clinical Decision Support Tool
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Ischemic Stroke
- Interventions
- Albumin, Saline
- Biological · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 841 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Concord, California + 48 more
- Conditions
- Acute Pain
- Interventions
- Drug: Bupivacaine 0.375% 20 mL, Drug: Bupivacaine 0.375% diluted to 0.1875%
- Drug
- Lead sponsor
- Anna Uskova
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B Cell Lymphoma, FL, HGBL, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B Cell Lymphoma, PMBCL, HGBL With MYC and BCL2 and/or BCL6 Rearrangements
- Interventions
- Prizloncabtagene Autoleucel
- Biological
- Lead sponsor
- AbelZeta Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 2
- States / cities
- Gilbert, Arizona • La Jolla, California
- Conditions
- Clinical High-Risk, Psychological
- Interventions
- Skills Group
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pregnancy, High Risk, Contraception
- Interventions
- Decision Aid, Routine Care
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 13 Years to 50 Years · Female only
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas